SCHEMBL4053451

SCHEMBL4053451

COc1ccc(-c2nc3ccc(-c4ccccc4C(F)(F)F)cc3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 5/20 0.51
TP53 P04637 4/20 0.51
LMNA P02545 3/20 0.51
HDAC6 Q9UBN7 1/20 0.50
GPR119 Q8TDV5 3/20 0.47
APP P05067 3/20 0.46
ALDH1A1 P00352 2/20 0.45
BACE1 P56817 1/20 0.45
KDM4E B2RXH2 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN5 P54829 1/20 0.45
UTRN P46939 1/20 0.44
POLB P06746 1/20 0.44
PIK3R1 P27986 1/20 0.44
PIK3CA P42336 1/20 0.44
TEK Q02763 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051500 0.90 NPC1 (0.54) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4058082 0.88 BACE1 (0.51) NPC1RAB9ASMN1; SMN2MAPTGPR119
SCHEMBL4059707 0.86 NPC1 (0.62) NPC1RAB9ASMN1; SMN2GPR119ALDH1A1
SCHEMBL4053287 0.86 GPR119 (0.54) NPC1HDAC6GPR119BACE1UTRN
SCHEMBL4052391 0.85 NPC1 (0.49) NPC1SMN1; SMN2GPR119ALDH1A1BACE1
SCHEMBL4054281 0.84 NPC1 (0.55) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4053408 0.81 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4059846 0.81 P2RY14 (0.47) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL4057762 0.80 BACE1 (0.46) MAPTBACE1KDM4EPTPN2PTPN1
SCHEMBL4051587 0.80 VSIR (0.51) NPC1RAB9AMAPTGPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885RAB9A 1184/4885SMN1; SMN2 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.